Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations
Carregando...
Citações na Scopus
35
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
GIDDING, Samuel S.
WIEGMAN, Albert
GROSELJ, Urh
FREIBERGER, Tomas
PERETTI, Noel
I, Kanika Dharmayat
DACCORD, Magdalena
BEDLINGTON, Nicola
SIKONJA, Jaka
RAY, Kausik K.
Citação
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, v.29, n.18, Special Issue, p.2301-2311, 2022
Resumo
Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country's healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.
Palavras-chave
Cholesterol, Familial hypercholesterolaemia, Myocardial infarction, Preventive cardiology, LDL cholesterol
Referências
- Ademi Z, 2020, ATHEROSCLEROSIS, V304, P1, DOI 10.1016/j.atherosclerosis.2020.05.007
- Ademi Z, 2014, J CLIN LIPIDOL, V8, P390, DOI 10.1016/j.jacl.2014.05.008
- Averna M, 2017, ATHEROSCLEROSIS SUPP, V29, P11, DOI 10.1016/j.atherosclerosissup.2017.07.001
- Beheshti SO, 2020, J AM COLL CARDIOL, V75, P2553, DOI 10.1016/j.jacc.2020.03.057
- Besseling J, 2015, ATHEROSCLEROSIS, V241, P597, DOI 10.1016/j.atherosclerosis.2015.06.011
- Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V316, P625, DOI 10.1001/jama.2016.9852
- Bogsrud MP, 2018, J CLIN LIPIDOL, V12, P375, DOI 10.1016/j.jacl.2017.11.009
- Bourbon M, 2008, ATHEROSCLEROSIS, V196, P633, DOI 10.1016/j.atherosclerosis.2007.07.019
- Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
- Gidding SS, 2016, JAMA CARDIOL, V1, P859, DOI 10.1001/jamacardio.2016.2871
- Groselj U, 2022, EUR HEART J, V43, P3209, DOI 10.1093/eurheartj/ehac224
- Groselj U, 2018, ATHEROSCLEROSIS, V277, P383, DOI 10.1016/j.atherosclerosis.2018.06.858
- Hu PW, 2020, CIRCULATION, V141, P1742, DOI 10.1161/CIRCULATIONAHA.119.044795
- Jones LK, 2020, RES SOC ADMIN PHARM, V16, P390, DOI 10.1016/j.sapharm.2019.06.006
- Kerr M, 2017, EUR HEART J, V38, P1832, DOI 10.1093/eurheartj/ehx111
- Khera AV, 2016, J AM COLL CARDIOL, V67, P2578, DOI 10.1016/j.jacc.2016.03.520
- Klancar G, 2015, J AM COLL CARDIOL, V66, P1250, DOI 10.1016/j.jacc.2015.07.017
- Kordonouri O, 2019, ATHEROSCLEROSIS, V280, P85, DOI 10.1016/j.atherosclerosis.2018.11.011
- Kreissl A, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1586-4
- Latkovskis G, 2018, ATHEROSCLEROSIS, V277, P347, DOI 10.1016/j.atherosclerosis.2018.06.011
- Luirink IK, 2019, NEW ENGL J MED, V381, P1547, DOI 10.1056/NEJMoa1816454
- Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
- McKay AJ, 2018, ATHEROSCLEROSIS, V275, P434, DOI 10.1016/j.atherosclerosis.2018.05.047
- Miserez AR, 2018, ATHEROSCLEROSIS, V277, P282, DOI 10.1016/j.atherosclerosis.2018.08.009
- Morris JK, 2012, AM J MED GENET A, V158A, P78, DOI 10.1002/ajmg.a.34368
- Mundal L, 2016, EUR J PREV CARDIOL, V23, P1962, DOI 10.1177/2047487316666371
- Myers KD, 2021, AM J PREVENT CARDIOL, V7, DOI 10.1016/j.ajpc.2021.100197
- O'Kane MJ, 2012, ADV THER, V29, P456, DOI 10.1007/s12325-012-0021-0
- Oliva J, 2009, REV ESP CARDIOL, V62, P57, DOI 10.1016/S0300-8932(09)70021-1
- Pelczarska A, 2018, ATHEROSCLEROSIS, V270, P132, DOI 10.1016/j.atherosclerosis.2018.01.036
- Petrulioniene Z, 2018, ATHEROSCLEROSIS, V277, P407, DOI 10.1016/j.atherosclerosis.2018.06.012
- Ramaswami U, 2020, ATHEROSCLEROSIS, V292, P178, DOI 10.1016/j.atherosclerosis.2019.11.012
- Robinson JG, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009778
- Sanin V, 2022, EUR J PUBLIC HEALTH, V32, P422, DOI 10.1093/eurpub/ckac007
- Schwiter R, 2020, J GENET COUNS, V29, P1142, DOI 10.1002/jgc4.1266
- Sjouke B, 2015, EUR HEART J, V36, P560, DOI 10.1093/eurheartj/ehu058
- Sustar U., 2022, GENET MED, V24, P2103, DOI [10.1016/j.gim.2022.06.010, DOI 10.1016/J.GIM.2022.06.010]
- Sustar U, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.936121
- Talasaz AH, 2021, PHARMACOTHERAPY, V41, P1009, DOI 10.1002/phar.2635
- Vallejo-Vaz AJ, 2018, ATHEROSCLEROSIS, V277, P234, DOI 10.1016/j.atherosclerosis.2018.08.051
- Versmissen J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2423
- Vrablik M, 2017, PHYSIOL RES, V66, pS1, DOI 10.33549/physiolres.933600
- Vuorio A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006401.pub2
- Wand H, 2020, J GENET COUNS, V29, P919, DOI 10.1002/jgc4.1194
- WHO Human Genetics Programme, 1997, FAM HYP FH REP WHO C
- Wiegman A, 2015, EUR HEART J, V36, P2425, DOI 10.1093/eurheartj/ehv157
- Wilemon KA, 2020, JAMA CARDIOL, V5, P217, DOI 10.1001/jamacardio.2019.5173
- WILLIAMS RR, 1993, AM J CARDIOL, V72, pD18, DOI 10.1016/0002-9149(93)90006-X
- Zuurbier LC, 2021, GENES-BASEL, V12, DOI 10.3390/genes12081168